ArticleFrontiers in oncology2025
Clinicopathological analysis of 13 patients with embryonal rhabdomyosarcoma of the female reproductive system in the Chinese population.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Adult cervical embryonal rhabdomyosarcoma: a literature review of 41 adult cases with an illustrative aggressive case.Gynecologic oncology reports · 2026Article
- Article
- Embryonal rhabdomyosarcoma of the uterine corpus in a postmenopausal Woman: A case report and literature Review.Gynecologic oncology reports · 2025Review
- Ovarian Rhabdomyosarcoma in Children.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Examine clinicopathological traits and differential diagnosis of ERMS in female reproductive system. Methods: Retrospectively assess 13 patients' data (Jan 2018 - Jun 2024, West China Second Univsity Hospital), covering clinical, histological, immunohistochemical aspects and literature review. Results: Age 2 months - 67 years (median 21), sites in cervix (5), ovaries (3), uterus (2). Non-specific symptoms. Lesions with grape-like etc. morphologies. Immunohistochemistry: the tumor cells expressed Myogenin (11/13), Desmin (13/13), MyoD1 (12/13) and Myoglobin (5/9). 4/5 had Discussion: ERMS is rare, diagnosed by histology and immunohistochemistry,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.